← Back to Clinical Trials
Recruiting NCT07287306

NCT07287306 Effects of BLa80 and LRa05 on the Gut Microbiota Metabolite Profile of Healthy Individuals

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07287306
Status Recruiting
Phase
Sponsor Wecare Probiotics Co., Ltd.
Condition Healthy Individuals
Study Type INTERVENTIONAL
Enrollment 375 participants
Start Date 2025-12-10
Primary Completion 2026-06-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
PlaceboBLa80LRa05

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 375 participants in total. It began in 2025-12-10 with a primary completion date of 2026-06-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Gut microbiota play a key role in polyphenol metabolism, participating in the breakdown of dietary components and producing various small molecule metabolites that affect human health. However, little is currently known about how gut microbes metabolize dietary compounds and produce bioactive metabolites. This study aims to use metabolomics to precisely identify food-derived metabolites in the blood to investigate whether probiotics (BLa80, LRa05) can enhance the breakdown of dietary components and improve their absorption and utilization in the human body.

Eligibility Criteria

Inclusion Criteria: 1. Male or female participants aged 18 to 60 years; 2. Healthy individuals; 3. Participants must provide written informed consent. Exclusion Criteria: 1. History of gastrointestinal surgery, other gastrointestinal diseases, metabolic disorders, immunodeficiency, hyperthyroidism, or cardiac or liver disease; 2. Use of immunosuppressants; 3. Pregnant or breastfeeding women; 4. Participants who have taken antibiotics or probiotics within the previous 3 months; 5. Planned surgery during the study period; 6. Patients with neurological disorders or psychiatric illness.

Frequently Asked Questions

Who can join the NCT07287306 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Healthy Individuals. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07287306 currently recruiting?

Yes, NCT07287306 is actively recruiting participants. Visit ClinicalTrials.gov or contact Wecare Probiotics Co., Ltd. to inquire about joining.

Where is the NCT07287306 trial being conducted?

This trial is being conducted at Guangzhou, China.

Who is sponsoring the NCT07287306 clinical trial?

NCT07287306 is sponsored by Wecare Probiotics Co., Ltd.. The trial plans to enroll 375 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology